Curis (NASDAQ:CRIS) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of Curis (NASDAQ:CRIS) from a strong sell rating to a hold rating in a report published on Monday,Zacks.com reports.

CRIS has been the topic of several other research reports. HC Wainwright reiterated a “buy” rating and set a $340.00 price objective on shares of Curis in a report on Friday, March 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of Curis in a research note on Monday, April 20th. Finally, Wall Street Zen upgraded shares of Curis to a “hold” rating in a report on Saturday, March 28th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $340.00.

Curis Stock Performance

Shares of NASDAQ CRIS opened at $4.65 on Monday. The stock has a market cap of $9.07 million, a P/E ratio of -0.20 and a beta of 3.08. The firm has a 50 day moving average price of $8.67 and a 200 day moving average price of $14.10. Curis has a 52-week low of $3.61 and a 52-week high of $39.00.

Curis (NASDAQ:CRIS) last released its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($25.00) EPS for the quarter, missing analysts’ consensus estimates of ($6.53) by ($18.47). Analysts predict that Curis will post -25.5 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC raised its position in Curis by 52.2% in the 1st quarter. Renaissance Technologies LLC now owns 366,740 shares of the biotechnology company’s stock valued at $201,000 after buying an additional 125,823 shares during the last quarter. Focused Wealth Management Inc grew its stake in shares of Curis by 83.4% during the 1st quarter. Focused Wealth Management Inc now owns 109,746 shares of the biotechnology company’s stock worth $60,000 after acquiring an additional 49,900 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Curis in the fourth quarter valued at approximately $26,000. Squarepoint Ops LLC lifted its position in shares of Curis by 46.2% in the fourth quarter. Squarepoint Ops LLC now owns 86,483 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 27,343 shares in the last quarter. Finally, Jane Street Group LLC boosted its holdings in Curis by 71.8% during the fourth quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 10,586 shares during the last quarter. 29.97% of the stock is owned by institutional investors and hedge funds.

About Curis

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.